Top Page
Advanced Medical Solutions
(LSE:AMS)
Advanced Medical Solutions (AMS) vs. iShares MSCI United Kingdom ETF (EWC)
Advanced Medical Solutions Business Overview & Revenue Model
Advanced Medical Solutions Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 177.52M | 126.21M | 124.33M | 108.60M | 86.80M | Gross Profit |
| 82.77M | 70.14M | 68.62M | 56.12M | 42.67M | EBIT |
| 10.45M | 18.88M | 26.09M | 20.60M | 11.69M | EBITDA |
| 29.68M | 31.40M | 34.94M | 29.45M | 17.53M | Net Income Common Stockholders |
| 7.09M | 15.89M | 20.41M | 17.48M | 8.58M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 17.04M | 60.16M | 82.26M | 72.97M | 53.83M | Total Assets |
| 389.00M | 289.17M | 281.09M | 249.51M | 238.56M | Total Debt |
| 86.56M | 9.14M | 9.75M | 9.86M | 11.12M | Net Debt |
| 69.53M | -51.02M | -72.51M | -63.10M | -42.71M | Total Liabilities |
| 147.48M | 44.97M | 44.47M | 36.83M | 36.34M | Stockholders Equity |
| 240.78M | 244.20M | 236.62M | 212.68M | 202.21M |
| Cash Flow | Free Cash Flow | |||
| 12.67M | 2.50M | 17.12M | 23.95M | 15.79M | Operating Cash Flow |
| 16.73M | 12.35M | 27.08M | 30.41M | 21.05M | Investing Cash Flow |
| -68.38M | -20.27M | -12.70M | -6.41M | -27.05M | Financing Cash Flow |
| 9.47M | -13.26M | -5.70M | -4.41M | -5.09M |
Advanced Medical Solutions Technical Analysis
Advanced Medical Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £5.87B | 39.48 | 11.12% | 1.90% | 3.94% | 41.63% | |
78 Outperform | £180.11M | 29.24 | 19.61% | 6.02% | 10.32% | 1.25% | |
72 Outperform | £462.68M | 64.80 | 2.93% | 0.72% | 40.66% | -55.09% | |
65 Neutral | £338.67M | 8.61 | 11.74% | ― | 38.80% | ― | |
59 Neutral | $355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
51 Neutral | £345.57M | ― | -369.20% | ― | 4.50% | 74.32% |
Advanced Medical Solutions Corporate Events
Advanced Medical Solutions Group plc has released its Annual Report and Accounts for the year ending December 31, 2024, and announced its Annual General Meeting scheduled for June 30, 2025. The report is accessible on the company’s website, and the AGM will take place in London. This announcement underscores AMS’s commitment to transparency and shareholder engagement, potentially strengthening its market position and stakeholder confidence.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group PLC has announced a change in its voting rights structure due to a recent transaction involving Octopus Investments Limited. The transaction resulted in Octopus Investments holding 11.95% of the voting rights, down from a previous 12.99%. This adjustment in voting rights may impact the company’s governance dynamics and reflects ongoing changes in shareholder composition.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced its total voting rights, with an issued share capital of 219,201,148 ordinary shares as of May 30, 2025. This information is crucial for shareholders to determine their notification obligations under the FCA’s Disclosure and Transparency Rules. The announcement reflects AMS’s commitment to transparency and regulatory compliance, potentially impacting shareholder engagement and market perception.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc has appointed Joh. Berenberg, Gossler & Co KG as a joint Corporate Broker alongside Investec Bank plc, effective immediately. This strategic move is expected to enhance AMS’s market presence and strengthen its financial advisory capabilities, potentially impacting its operations and industry positioning positively.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc announced recent share transactions involving its directors and employees. Susan Searle, a Non-Executive Director, and her husband purchased shares, while CEO Chris Meredith and CFO Eddie Johnson engaged in transactions to reinvest in the company’s Share Incentive Plan (SIP) and Employee Share Purchase Plan (ESPP). These transactions reflect the directors’ commitment to the company’s growth and align their interests with those of shareholders. The moves are expected to strengthen their beneficial ownership and demonstrate confidence in the company’s future prospects.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc has announced a delay in its Annual General Meeting (AGM) to 30 June 2025 due to unforeseen changes within its audit team at Deloitte LLP. Consequently, the record date for the proposed final dividend of 1.83p per share has been moved to 20 June 2025, with the dividend payment scheduled for 17 July 2025, pending shareholder approval at the AGM. This adjustment reflects the company’s commitment to maintaining transparency and adapting to operational changes, which may impact shareholder expectations and financial planning.
The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Advanced Medical Solutions Group plc has announced the granting of new nil-cost share options to its directors under the Long Term Incentive Plan (LTIP), based on performance criteria such as Earnings Per Share and Total Shareholder Return. This move is part of the company’s strategy to align management incentives with shareholder interests, potentially impacting its market positioning and stakeholder confidence.
Advanced Medical Solutions Group plc announced its total issued share capital as of April 30, 2025, which comprises 218,107,619 ordinary shares with voting rights. This information is essential for shareholders to determine their notification obligations under the FCA’s Disclosure and Transparency Rules, potentially impacting shareholder engagement and compliance activities.
Advanced Medical Solutions Group plc announced that Montagu Private Equity LLP has decided not to make an offer for the company, as confirmed by Montagu’s adherence to Rule 2.8 of the City Code on Takeovers and Mergers. The AMS Board expressed satisfaction with the company’s performance and remains confident in its growth strategy, which is expected to drive value creation for shareholders.
Advanced Medical Solutions Group plc announced that its issued share capital as of March 31, 2025, consists of 217,994,699 ordinary shares with voting rights, with no shares held in treasury. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
Advanced Medical Solutions Group plc has appointed Susan Searle as an Independent Non-Executive Director, enhancing its board with her extensive experience in healthcare and other sectors. This strategic appointment is expected to bolster AMS’s growth trajectory and strengthen its governance as the company continues to expand its global presence in the tissue-healing technology market.
Advanced Medical Solutions Group plc (AMS) has acknowledged an announcement by Montagu Private Equity LLP regarding a potential offer for the company. However, AMS has not received a formal proposal, and there is no certainty that an offer will be made. The company is now in an ‘offer period’ as per the City Code on Takeovers and Mergers, with Montagu required to make a decision by April 24, 2025. This development places AMS under scrutiny, potentially impacting its market positioning and shareholder interests.
Advanced Medical Solutions Group plc reported strong financial results for 2024, with a 43% increase in revenue to £177.5 million, driven by the successful integration of Peters Surgical and Syntacoll acquisitions. The company saw significant growth in its US LiquiBand® product and launched the LIQUIFIX™ hernia fixation device in the US, contributing to record sales. Despite a decrease in reported profit due to acquisition costs, AMS remains optimistic about future growth, supported by strategic initiatives and an increased dividend proposal, reflecting confidence in its outlook.
Advanced Medical Solutions Group plc has announced a change in its board leadership as Liz Shanahan steps down as Chair and Director for personal reasons, effective March 31, 2025. Grahame Cook, currently the Senior Independent Non-Executive Director, will succeed her as Non-Executive Chair. This transition occurs as AMS is poised to advance its business in the surgical sector, particularly following the acquisition of Peters Surgical. The company also announced that it is in the process of appointing an additional Non-Executive Director, highlighting its commitment to strengthening its leadership team.